Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Technology appraisal guidance
Reference number: TA983
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.